Back to search
FDAFDA · Food and drugs·Recall number D-1143-2023

Nexlizet (bempedoic acid and ezetimibe), 180ng/18mg, 30 tablets, Rx only, Manufactured for: Esperion Therapeutics, Inc, Ann Arbor, MI 48108, NDC 72426-818-03

Published September 13, 2023 · Recall initiated: August 16, 2023

Summary

FDA records drug Class III recall D-1143-2023, published September 13, 2023 and initiated August 16, 2023. Recalling firm: Esperion; Status: Completed; Reported quantity: 45,240 bottles; Lot: Lot# 1904872, Exp 1/31/2025; 1950377, Exp 6/30/2025. Class III means the product is not likely to cause adverse health consequences.

Status when published: Completed — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed dissolution specifications: below specification results at stability 12-month

What to do

Voluntary: Firm initiated · Letter

Get an email if NEXLIZET has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
NEXLIZET
Manufacturer
Esperion
Distributor
Nationwide USA
Lot
Lot# 1904872, Exp 1/31/2025; 1950377, Exp 6/30/2025
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Nexlizet (bempedoic acid and ezetimibe), 180ng/18mg, 30 tablets, Rx only, Manufactured for: Esperion Therapeutics, Inc, Ann Arbor, MI 48108, NDC 72426-818-03 recalled?

Yes. FDA published recall D-1143-2023 on September 13, 2023. Reported hazard: Failed dissolution specifications: below specification results at stability 12-month

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: NEXLIZET.